Amneal Pharmaceuticals (AMRX) Set to Announce Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) will issue its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.570-0.630 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The company had revenue of $701.78 million during the quarter, compared to analyst estimates of $657.43 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Trading Up 3.0 %

NASDAQ:AMRX opened at $8.50 on Thursday. Amneal Pharmaceuticals has a 12 month low of $3.96 and a 12 month high of $8.95. The stock has a 50 day moving average of $8.53 and a two-hundred day moving average of $7.51. The firm has a market cap of $2.63 billion, a P/E ratio of -13.71 and a beta of 1.17.

Wall Street Analysts Forecast Growth

AMRX has been the subject of several research reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research note on Friday, September 6th. Barclays upped their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, Truist Financial upped their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.